Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Spyre Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SYRE
Nasdaq
8731
https://spyre.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Spyre Therapeutics Inc
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- May 9th, 2024 8:02 pm
Spyre Therapeutics Announces Grants of Inducement Awards
- May 3rd, 2024 9:00 pm
Spyre Therapeutics Announces $180 Million Private Placement
- Mar 18th, 2024 12:00 pm
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Feb 29th, 2024 9:05 pm
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
- Feb 26th, 2024 12:30 pm
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
- Feb 8th, 2024 12:30 pm
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
- Feb 5th, 2024 12:30 pm
Spyre Therapeutics raises $180 million to advance anti-inflammatory drugs
- Dec 8th, 2023 12:19 pm
Scroll